Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Under the terms of the deal, Bedford, Mass.-based Stoke STOK will retain exclusive rights for the treatment called ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...

Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...

Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...

H.C. Wainwright raised the firm’s price target on Stoke Therapeutics (STOK) to $47 from $35 and keeps a Buy rating on the shares. Stoke and ...